Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn gGmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At the Klinik für Hämatologie und Onkologie, researchers focus on blood‑related malignancies, especially Chronic Lymphocytic Leukemia and its aggressive transformation into Richter transformation. Ongoing studies aim to improve progression‑free survival by testing novel combinations of targeted agents.
- Evaluation of BTK inhibitor‑based regimens in elderly patients with untreated DLBCL
- Comparison of fixed‑duration venetoclax‑obinutuzumab versus continuous ibrutinib in treatment‑naïve CLL
- Investigation of immunotherapy plus BTK inhibition for CLL‑derived Richter transformation
- Assessment of retreatment strategies with venetoclax‑obinutuzumab in CLL
The Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn gGmbH supports these trials to advance therapeutic options for patients with hematologic cancers.
Neoplasms
The site also conducts research on solid and lymphoid cancers, notably various subtypes of Diffuse Large B‑Cell Lymphoma. Trials are designed to test whether adding new agents to reduced‑intensity chemotherapy can extend disease control in older adults.
- Adding acalabrutinib to R‑miniCHOP for patients over 60 with untreated DLBCL
- Studying outcomes of obinutuzumab‑venetoclax versus obinutuzumab‑chlorambucil in CLL with comorbidities
- Exploring targeted therapy combinations for rare DLBCL variants such as EBV‑positive and HHV8‑positive forms
- Monitoring safety and efficacy of BTK and BCL‑2 inhibition across multiple lymphoma subtypes
These investigations reflect the department’s commitment to personalized treatment strategies for diverse neoplastic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 67 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 66 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1University Of Cologne4active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1University Of Cologne8trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn gGmbH
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 67 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 7 | Unknown | 2014-12-18 | 2025-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.